Skip to main content
Welcome to "The Poster!" To become a subscriber and start getting updates on new content, subscribe now!

In the News

Students | Student Poster Days Showcase Young Researchers

Student interns presented their research to the NCI at Frederick community during the annual Student Poster Days event, held in the Building 549 lobby and the Advanced Technology Research Facility (ATRF) atrium over two days.

Outreach | Frederick National Lab Encourages Healthy Living at the Annual In The Street Festival

While it was the pleasant weather, live music, and scores of vendors that drew thousands to Frederick’s 2017 In The Street festival, it was the eye-catching activities and prizes that drew attendees to the Frederick National Laboratory for Cancer Research tent.

Publications | Platinum Publications, July 26–August 30, 2017

Platinum Publications are selected from articles by NCI at Frederick scientists published in 42 prestigious science journals. This list represents articles published during the time period shown above, as generated from PubMed. Articles designated as Platinum Highlights are noteworthy articles selected from among the most recently published Platinum Publications.

Science & Technology | NCI Scientists Create New Assay, Identify Novel Therapeutic Compounds, and Take Places on Front Lines of Cancer Research

A team of scientists and specialists from NCI at Frederick, NCI at Bethesda, the Frederick National Laboratory for Cancer Research, and Data Management Services, Inc., has developed the first method for identifying natural products that could increase the effectiveness of camptothecin-based cancer treatments.

Science & Technology | NCI, FNLCR Help Launch Pediatric MATCH Precision Medicine Trial

The National Cancer Institute and Children’s Oncology Group recently opened enrollment for a new Phase II trial of personalized precision cancer therapies. Called the Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH), the trial seeks to treat children and adolescents aged 1­–21 whose solid tumors have failed to respond to or re-emerged after traditional cancer treatments.